Children’s National Hospital, based in Washington, D.C., celebrates 150 years of pediatric care, research and commitment to community. Volunteers opened the hospital in 1870 with 12 beds for children displaced after the Civil War. Today, 150 years stronger, it is among the nation’s top 10 children’s hospitals. It is ranked No. 1 for newborn care for the fourth straight year and ranked in all specialties evaluated by U.S. News & World Report. Children’s National is transforming pediatric medicine for all children. In 2020, construction will be complete on the Children’s National Research & Innovation Campus, the first in the nation dedicated to pediatric research. Children’s National has been designated twice as a Magnet® hospital, demonstrating the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers in the D.C., metropolitan area, including the Maryland and Northern Virginia suburbs. Children’s National is home to the Children’s National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation and is the nation’s seventh-highest NIH-funded children’s hospital. It is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels.
Greater Washington had its second-biggest venture funding year in at least a decade in 2017, with startups across the metro area raking in more than $1.55 billion.
TAI Diagnostics said earlier this week that it had closed a $10 million round of funding and forged a new partnership with United Therapeutics (NASDAQ: UTHR).
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.
In covering the D.C. innovation economy comes the inevitable: funding news. Trust us, there’s a lot of it floating around the D.C. metro area. Here’s a roundup of all of the major funding news from the region in December:
Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two new members to their Board of Directors for a term of three years. The election took place on December 14, 2017 at the Virginia Bio Annual Membership meeting in Richmond, Virginia. The new directors will begin their terms effective on January 1, 2018.
Venture capitalists poured $1.55 billion into D.C. area technology start-ups last year, an industry report found, as a handful of so-called megadeals propelled the region to a six-year high for technology investing in 2017.
Personal Genome Diagnostics, a Baltimore-based cancer diagnostics company, has raised $75 million to expand access to genomic testing for cancer patients.
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.